# MYD88

Source: https://onco.cc/targets/myd88/  
OnCo record `myd88` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MYD88 (Myeloid differentiation primary response protein MyD88) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 4 more.

## Summary

Adapter protein involved in the Toll-like receptor and IL-1 receptor signalling pathway in the innate immune response. Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Increases IL-8 transcription.

CIViC holds 5 clinical evidence items and 0 assertions across 2 variants, naming Paclitaxel, Ibrutinib, IRAK-1/4 Inhibitor and IMG-2005-5. Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.98, genetic association 0.00, somatic mutation 0.95). IntOGen calls it a driver in 10 cohorts (10 activating, 0 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: MYD88 innate immune signal transduction adaptor; Myeloid differentiation primary response protein MyD88
- Tags: cancer-genes-wave
- Symbol: MYD88
- Class: oncogene
- Biology: Adapter protein involved in the Toll-like receptor and IL-1 receptor signalling pathway in the innate immune response. Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Increases IL-8 transcription. Involved in IL-18-mediated signalling pathway. Activates IRF1 resulting in its rapid migration into the nucleus to mediate an efficient induction of IFN-beta, NOS2/INOS, and IL12A genes. Upon TLR8 activation by GU-rich single-stranded RNA (GU-rich RNA) derived from viruses such as SARS-CoV-2, SARS-CoV and HIV-1, induces IL1B release through NLRP3 inflammasome activation. Location: Cytoplasm; Nucleus (UniProt). Locus 3p22.2 (HGNC).
- Where found: Non-Hodgkin lymphoma: Open Targets association 0.83 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL); Leukaemia: Open Targets association 0.74 with leukaemia (MONDO_0005059); Breast cancer: Open Targets association 0.54 with breast cancer (MONDO_0007254); CIViC evidence names this disease; Diffuse large B-cell lymphoma: Open Targets association 0.72 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease; Acute lymphoblastic leukaemia: Open Targets association 0.70 with acute lymphoblastic leukaemia (MONDO_0004967); Chronic lymphocytic leukaemia: Open Targets association 0.70 with B-cell chronic lymphocytic leukaemia (MONDO_0004948); CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 4 therapies; IntOGen calls it an activating (Act) driver in 10 cohorts; CIViC holds 5 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Lymphoplasmacytic Lymphoma.

## Sources

- HGNC HGNC:7562: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7562
- UniProt Q99836: https://www.uniprot.org/uniprotkb/Q99836/entry
- NCBI Gene 4615: https://www.ncbi.nlm.nih.gov/gene/4615
- Ensembl ENSG00000172936: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172936

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- pathways: [B-cell receptor / BTK signalling (to NF-κB)](https://onco.cc/pathways/bcr-signalling/)
- trials: [A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4](https://onco.cc/trials/nct04274738/)

---
JSON: https://onco.cc/api/v1/entities/myd88.json